中图分类号R559；R969.3 文献标志码A 文章编号 1001-0408(2025)14-1781-05

    DOI 10.6039/j.issn.1001-0408.2025.14.16

    ABSTRACTOBJECTIVETo explore the eficacyand safetyof ruxolib in the treatmentof myelofibrosis (MF).METHODS Aretrospectivecollctionofdata wasconductedon42MFpatients whoweretreated withruxolitibinastandardized manerfor morethan6monthsintheThirdPeople'sHospitalofBengbufromSeptember2018toApril2024.Theclinicalsymptomscores， spleensizereduction，andMFgradingof thepatientsbeforeandaftertreatment wereanalyzed.Addionally，theoccurrenceof adverse reactions withacausalityassessmentresultof“definite”“probable”or“posible”wasrecorded.Thepatients’survival status was follwedup.RESULTS After6monthsof reatment，both clinicalsymptomscoresandthetotalscore weresignificantly decreased than before treatment ( ?Plt;0.05 ).The length and thickness of the spleen were significantly shorter than before treatment ( ?lt;0.05 ).MFclasificationin5patients decreasedby1levelcompared with baseline，1casewas level2and droppedto level0， 14patientsremained stable.Themainadversereactionswereanemia(26cases)，thrombocytopenia(14cases) ......